Salmerix (salmeterol, fluticasone propionate) powder for inhalation doz.50 mcg/250 mcg/dose 60 doses ing.№1


Bronchial asthma Regular treatment of bronchial asthma in patients who are indicated for combination therapy with a long-acting β2-aderonomimetic and an inhaled corticosteroid, namely: patients with insufficient disease control on the background of continuous monotherapy with inhaled corticosteroid with periodic use (if necessary) of short-acting β2-aderonomimetics; patients with adequate control of the disease on the background of treatment with inhaled corticosteroid and β2-adrenomimetikam a long-acting. Chronic obstructive pulmonary disease Maintenance therapy of chronic obstructive pulmonary disease (COPD) in patients with FEV1 < 60% of the proper values (before inhalation of the bronchodilator) and repeated exacerbations in the anamnesis, who have severe symptoms of the disease persist, despite regular therapy with bronchodilators.

Category: Manufacturer: Poland


Salmerix Composition and form of release
The main active ingredients are salmeterol, fluticasone propionate.
Excipients: lactose.
The drug is produced in the form of metered-dose powders, which are packed in a special inhaler, 60 doses in one inhaler.
1 dose of powder contains 50 mcg of salmeterol and 250mcg of fluticasone propionate.

Pharmacological properties
This drug belongs to adrenergic pharmaceuticals and their combinations, which are used in the form of inhalation.
This drug belongs to the group of bronchodilating agents, with salmeterol and fluticasone propionate as active active ingredients.
Salmeterol, in particular, is a selective agonist of beta-two-adrenergic receptors, which is characterized by a long-term effect (acts for half a day). Its molecular structure has a long side link that is able to bind to the outside of the receptor.
Salmeterol has a great effect in preventing the appearance of bronchospasm triggered by exposure to histamines (the most common cause of asthmatic attacks), while it has a longer bronchodilation when compared with ordinary short-term beta-two-adrenergic receptor agonists.
It has the property of effective and long-term inhibition of the release of mediators of certain cells in the lung tissues, in particular, histamines, leukotrienes, and others.
Able to cause suppression of an allergic reaction in the early and late stages. Even after a single dose has been administered, there is a decrease in bronchial hyperreactivity. Half an hour after the end of the effect of expansion of the bronchi, inhibition of the late stage of an attack of bronchospasm occurs.
Fluticasone is a glucocorticosteroid used for topical treatment. If it is administered in the form of an inhalation injection, then the drug enters directly into the lower respiratory tract (trachea, bronchi, lungs). In this case, a pronounced anti-inflammatory effect is produced, as a result of which the activity of painful symptoms decreases, the frequency of exacerbations of diseases in which obstruction of the lower respiratory organs occurs.

Salmerix Indications
This drug is prescribed for the treatment of chronic bronchial asthma, when the patient is recommended to be treated with a combination of long-acting β2-agonists and inhaled GCS. In particular, for:

  • patients with insufficient control of bronchial asthma during therapy with inhaled GCS and short-acting β2-agonists;
  • patients with adequate control of bronchial asthma during therapy with inhaled GCS and long-acting β2-agonists.

This drug is not used if the patient is allergic to one of its constituent drugs, including auxiliary drugs.
For the treatment of children can be used from 12 years of age.

Application during pregnancy and lactation
This drug can be used to treat pregnant women only if their life is at risk and with careful weighing of the benefit / harm ratio by the attending physician.
Lactation is suspended for the duration of treatment with this drug.

Method of administration and dosage
This drug is used on a regular basis, starting with inhalation twice a day and switching to using the drug once a day. The dose is determined by the doctor.
The drug is used even if asthma attacks do not occur.
The introduction of the drug occurs by inhalation of a dose of the drug in the form of microscopic doses of powder, using an inhaler. The use of the inhaler is explained in detail in the attached instruction sheet.
In order for the drug to enter the windpipe when inhaling, you need:

  • shake the inhalation can;
  • exhale the air from the lungs as much as possible;
  • insert an aerosol mouthpiece into your mouth, clasping it with your lips on all sides;
  • by pressing on the bottom of the can, take a deep breath;
  • hold your breath as long as possible.

If the patient previously had nocturnal attacks of bronchial asthma, then this 1 dose is inhaled before going to bed. If daytime attacks are more frequent, then the dose of the drug is inhaled in the morning.
After use, rinse your mouth with water to avoid oral candidiasis.

Overdose with this drug can cause increased side effects. Most often observed:

  • trembling limbs, tachycardia;
  • headache, hypokalemia, hyperkalemia;
  • decreased work of the adrenal glands (recovers on its own);
  • nausea, hypoglycemia, convulsions.

Treatment – selective beta-blockers, drug withdrawal.

Side effects
The drug can cause side reactions in the form of:

  • oral candidiasis, pneumonia, bronchitis;
  • allergic reactions – angioedema, rash, shortness of breath, anaphylactic shock;
  • oppression of the adrenal glands, decrease in bone mineralization, growth retardation in children;
  • hypokalemia, hyperglycemia;
  • nausea, dyspeptic symptoms;
  • nervousness, insomnia;
  • headache, tremors of the limbs;
  • cataracts, glaucoma;
  • tachycardia, arrhythmias;
  • nasopharyngitis, sinusitis, pharyngitis;
  • contusion;
  • muscle spasms, arthralgia, myalgia, limb fractures.

Storage conditions and periods Salmerix 
Shelf life is 2 years.
Storage temperature should not exceed 30 ° C.